Drug intelligence / Profile preview

influenza and COVID-19 combination B

Development stage: Approved
Lead developer: Pfizer
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Influenza and COVID-19 combination B is a combined modified RNA vaccine candidate developed by BioNTech SE and Pfizer. It is designed to provide protection against both influenza and SARS-CoV-2 by delivering mRNA that instructs the body's cells to produce antigens from both viruses, thereby triggering an immune response. This vaccine aims to simplify immunization practices by offering simultaneous protection against these two common respiratory diseases.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on influenza and COVID-19 combination B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on influenza and COVID-19 combination B.

Explore the full profile